Actuate Therapeutics Enters Material Agreement, Files 8-K
Ticker: ACTU · Form: 8-K · Filed: Jun 26, 2025 · CIK: 1652935
| Field | Detail |
|---|---|
| Company | Actuate Therapeutics, Inc. (ACTU) |
| Form Type | 8-K |
| Filed Date | Jun 26, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, filing
Related Tickers: ACTU
TL;DR
ACTU filed an 8-K for a material agreement and equity sales. Keep an eye on this.
AI Summary
Actuate Therapeutics, Inc. announced on June 25, 2025, that it entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and filed financial statements and exhibits. The filing was made on June 26, 2025.
Why It Matters
This 8-K filing indicates significant corporate activity, including a new material agreement and equity transactions, which could impact the company's financial standing and future operations.
Risk Assessment
Risk Level: medium — Material definitive agreements and unregistered equity sales can introduce financial and operational risks that are not fully disclosed in an 8-K.
Key Players & Entities
- Actuate Therapeutics, Inc. (company) — Registrant
- June 25, 2025 (date) — Date of earliest event reported
- June 26, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of Incorporation
- 47-3044785 (identifier) — IRS Employer Identification No.
- 1751 River Run, Suite 400 Fort Worth, Texas 76107 (address) — Principal Executive Offices
- Apotheca Therapeutics, Inc. (company) — Former company name
- 20150911 (date) — Date of former company name change
FAQ
What is the nature of the material definitive agreement entered into by Actuate Therapeutics, Inc.?
The filing states that Actuate Therapeutics, Inc. entered into a material definitive agreement on June 25, 2025, but the specific details of this agreement are not provided in the provided text.
What type of equity securities were sold in the unregistered sales reported?
The filing mentions unregistered sales of equity securities, but the specific type and details of these securities are not disclosed in the provided text.
When was Actuate Therapeutics, Inc. incorporated and in which state?
Actuate Therapeutics, Inc. was incorporated in Delaware.
What is the principal executive office address for Actuate Therapeutics, Inc.?
The principal executive offices are located at 1751 River Run, Suite 400, Fort Worth, Texas 76107.
Has Actuate Therapeutics, Inc. undergone a name change previously?
Yes, the company was formerly known as Apotheca Therapeutics, Inc., with a date of name change on September 11, 2015.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 26, 2025 regarding ACTUATE THERAPEUTICS, INC. (ACTU).